
ACTION REQUIRED

Updated Share Splits for Intravenous Immunoglobulins
Customer Letter # 2025-04

2025-02-04

Dear Colleagues:

Canadian Blood Services would like to inform customers of upcoming changes to share splits for intravenous immunoglobulins (IVIg). As noted in prior Customer Letters, the management of IVIg brands is dynamic and ongoing. Canadian Blood Services works hard to limit the magnitude and disruption of changing share splits, but it should be expected that the targets will continue to change from time to time. Canadian Blood Services is committed to supporting hospital customers in managing their IVIg supply by sharing new information in a timely manner.

Table 1 outlines the current and updated projected national share splits for IVIg. Hospitals receive regular reports showing their IVIg brand share splits and the target share splits. This allows hospitals to monitor their progress toward the target and take appropriate action.

Table 1: Updated share splits for IVIg brands

Product	Estimated supply share Jan 1, 2025 – Mar 31, 2025	Estimated supply share April 1, 2025 – Mar 31, 2026
Gammagard	17%	15%
Gamunex/IGIVnex	51%	57%
Privigen	31%	28%
Octagam	1%	0%

It is important to note that although the supply mix is being adjusted, a sufficient supply of IVIg continues to be maintained. Canadian Blood Services sincerely appreciates your continued support as we manage these changes collaboratively.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Dr. Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program